SECOX as Neoadjuvant Therapy in Patients With Locally Advanced HCC
Status:
Completed
Trial end date:
2019-04-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the resectability after treatment with SECOX
(sorafenib, capecitabine, oxaliplatin) as neoadjuvant therapy in patients with locally
advanced hepatocellular carcinoma